Results 91 to 100 of about 2,475,393 (270)

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

Clinical Pharmacology: Advances and Applications, 2016
Melanie Davies,1,2 Sudesna Chatterjee,1,2 Kamlesh Khunti1,2 1Diabetes Research Centre, University of Leicester, 2Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK Abstract: Worldwide, an estimated 200 million people ...
Davies M, Chatterjee S, Khunti K
doaj  

Purification and Identification of Novel Dipeptidyl Peptidase IV Inhibitory Peptides Derived from Bighead Carp (Hypophthalmichthys nobilis)

Foods
Dipeptidyl peptidase IV (DPP-IV) inhibitors are widely used in treating type 2 diabetes due to their ability to lower blood glucose levels. However, synthetic versions often lead to gastrointestinal side effects.
Hanzhi Zheng, Leyan Zhao, Yushuo Xie, Yuqing Tan   +3 more
doaj   +1 more source

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors

, 2015
Watshara Shoombuatong,1 Veda Prachayasittikul,1,2 Nuttapat Anuwongcharoen,1 Napat Songtawee,1 Teerawat Monnor,1 Supaluk Prachayasittikul,1 Virapong Prachayasittikul,2 Chanin Nantasenamat1,2 1Center of Data Mining and Biomedical Informatics, 2Department ...
Prachayasittikul V, Shoombuatong W, Songtawee N, Anuwongcharoen N, Monnor T, Prachayasittikul S, Nantasenamat C   +6 more
core  

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome. [PDF]

Int J Appl Basic Med Res, 2023
Suman RK, Borde MK, Mohanty IR, Singh HK.   +3 more
europepmc   +1 more source

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats

, 2016
Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess ...
Borde MK, Maheshwari U, Suman RK, Mohanty IR, Deshmukh YA   +4 more
core  

Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus

Journal of Diabetes Investigation, EarlyView.
This study evaluated serum miRNAs as biomarkers in adult patients with SPIDDM. Serum miRNAs were measured at the time of SPIDDM (probable) diagnosis, and miR‐150‐5p was inversely associated with CPI at the last outpatient visit, suggesting its potential utility for predicting subsequent insulin secretory decline.
Hideyuki Okuma, Takahiro Tsutsumi, Masashi Ichijo, Tetsuro Kobayashi, Kyoichiro Tsuchiya   +4 more
wiley   +1 more source

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents. [PDF]

Molecules, 2022
Mohammad BD, Baig MS, Bhandari N, Siddiqui FA, Khan SL, Ahmad Z, Khan FS, Tagde P, Jeandet P.   +8 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy

, 2010
Mary Elizabeth Cox1, Jennifer Rowell1, Leonor Corsino1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology,
Mary Elizabeth Cox, et al, Jennifer Rowell, Leonor Corsino   +3 more
core  

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source